@article{fdi:010092938,
  title = {{H}uman {A}frican trypanosomiasis},
  author = {{L}ejon, {V}eerle and {L}indner, {A}. {K}. and {F}ranco, {J}. {R}.},
  editor = {},
  language = {{ENG}},
  abstract = {{H}uman {A}frican trypanosomiasis or sleeping sickness is caused by infection with {T}rypanosoma brucei gambiense or {T}rypanosoma brucei rhodesiense parasites, which are transmitted by tsetse flies in sub-{S}aharan {A}frica. {C}ontrol of human {A}frican trypanosomiasis is based on case detection, treatment, and vector control. {I}n the past decade, simple rapid diagnostic tests were introduced for gambiense human {A}frican trypanosomiasis, facilitating screening in primary health-care facilities. {A} new oral drug, fexinidazole, became the first-line treatment for gambiense human {A}frican trypanosomiasis without severe meningo-encephalitic disease, as well as for rhodesiense human {A}frican trypanosomiasis. {M}edical interventions, in some areas combined with tiny target-based vector control, have substantially reduced human {A}frican trypanosomiasis incidence, despite temporary disruptions to health-care systems. {T}he elimination of human {A}frican trypanosomiasis as a public health problem has been achieved, and elimination of gambiense human {A}frican trypanosomiasis transmission is now targeted for 2030. {I}mproved diagnostics and drugs, continued involvement of populations at risk of disease, health staff, national authorities, and partners and donors all contribute to achieve this goal.},
  keywords = {{AFRIQUE}},
  booktitle = {},
  journal = {{L}ancet},
  volume = {405},
  numero = {10482},
  pages = {937--950},
  ISSN = {0140-6736},
  year = {2025},
  URL = {https://www.documentation.ird.fr/hor/fdi:010092938},
}